Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Established in 1950, Taro Pharmaceutical Industries Ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taro Pharmaceutical (TARO) to Report Q1 Results: Wall Street Expects Earnings Growth

Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Why Taro Pharmaceutical (TARO) Could Be Positioned for a Slump

Taro has inherited a top tier balance sheet due to management's refusal to engage in LBOs during the drug acquisition bubble of 2014-2015.

Taro Pharmaceutical Is Thriving Against The Generic Drug Apocalypse - Shares Are Undervalued

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q4 2019 Results - Earnings Call Transcript

Taro (TARO) delivered earnings and revenue surprises of -32.74% and -5.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Misses Q4 Earnings and Revenue Estimates

News for Taro Pharmaceutical Industries Stock (TARO)